Detalhe da pesquisa
1.
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
Int J Clin Pract
; 2022: 6475014, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35685566
2.
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
J Urol
; 205(5): 1421-1429, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356445
3.
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study.
Int J Clin Pract
; 75(5): e13937, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33332699
4.
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
J Urol
; 204(2): 316-324, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068484
7.
Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis.
Drugs Context
; 112022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36303599
8.
Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
Neurogastroenterol Motil
; 34(12): e14448, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35975404
9.
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR.
Adv Ther
; 39(2): 959-970, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921665
10.
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.
Drugs Aging
; 38(2): 137-146, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469832
11.
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Adv Ther
; 38(11): 5452-5464, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34537953
12.
Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza.
Clin Transl Sci
; 13(1): 157-168, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31664778
13.
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
AIDS Res Hum Retroviruses
; 34(8): 672-679, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29732898
14.
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
Lancet Respir Med
; 5(2): 135-146, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28094141
15.
Intravenous Zanamivir in Hospitalized Patients With Influenza.
Pediatrics
; 140(5)2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051331
16.
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis.
PLoS One
; 10(11): e0142081, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26556603
17.
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Clin Infect Dis
; 39(3): 411-8, 2004 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15307010
18.
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors.
Antimicrob Agents Chemother
; 46(3): 731-8, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11850255
19.
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
Lancet
; 359(9312): 1121-2, 2002 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-11943262